Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Ortho EVRA Marketing Could Stress Convenience Over Oral Contraceptive

  • News

Executive Summary

Ortho-McNeil will likely highlight the convenience of a once-weekly application for its contraceptive patch Ortho EVRA over daily oral contraceptives

You may also be interested in...



J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic

J&J will step up promotion of Ortho EVRA in the fourth quarter, marking the end of supply constraints for the contraceptive patch

J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic

J&J will step up promotion of Ortho EVRA in the fourth quarter, marking the end of supply constraints for the contraceptive patch

Watson “Authorized” Generic Tri-Cyclen Will Share Market With Barr

Watson will launch an "authorized" generic version of Ortho-McNeil'soral contraceptive Ortho Tri-Cyclen when Barr enters the market with its generic under an agreement between Watson and Ortho announced Oct. 28

Table

View full table

Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS038904

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By